Medical funding

Chinese biomedical CRO seals $77m fundraising for R&D push

Animal gene modifier Beijing Biocytogen managed to draw on both government and private capital for its Series D funding round.

Beijing Biocytogen, a contract research organisation which specialises in gene-modified animal models, said it has raised Rmb543 million ($77 million) from a group of government-owned and private investors in its Series D round of funding.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media